APCext : Effect of Temporary Porto-caval Shunt During Liver Transplantation on Function of Liver Graft From Extended Criteria Donor

Last updated: September 20, 2024
Sponsor: Rennes University Hospital
Overall Status: Active - Recruiting

Phase

N/A

Condition

Liver Transplantation

Treatment

temporary porto-caval shunt

Clinical Study ID

NCT02784119
2016-A00612-49
35RC15_8975
  • Ages > 18
  • All Genders

Study Summary

The success of orthotopic liver transplantation (OLT) in treatment of liver malignancy and endstage liver disease has led to an increase in the gap between patients on waiting-lists and available liver grafts. In order to compensate for this scarcity, use of liver grafts harvested from extended criteria donors (ECD) has become more and more frequent.

However, these ECD grafts are known to be associated with a higher rate of primary non function (PNF) or early allograft dysfunction (EAD) because of a greater vulnerability to ischemia-reperfusion injury (IRI).

During OLT, the clamping of the portal vein induces blood congestion in the splanchnic territory leading to increased gut permeability, bacterial translocation and release of endotoxin and pro-inflammatory cytokines at revascularisation, which exacerbate IRI.

Realisation of a temporary porto-caval shunt (TPCS) (i.e. end to side anastomosis between the portal vein and infrahepatic vena cava) during the anhepatic phase, avoids splanchnic congestion and could therefore decrease IRI and improve liver graft function. However, TPCS remains poorly used as no randomised trial succeeds to show its benefit on liver function due to lack of power.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Age ≥ 18 years old

  • Candidate of liver transplantation

  • With cirrhosis from any etiology

  • Model For End-Stage Liver Disease (MELD) score < 25

  • Transplanted with a liver graft harvested from an extended criteria donor defined aspresence of at least one of the following criteria:

  • Donor age > 65 years old

  • Intensive care unit stay > 7 days

  • BMI > 30

  • Natremia > 155 mmol/L

  • Aspartate aminotransferase (ASAT) > 150 IU/mL

  • Alanine aminotransferase (ALAT) > 170 IU/mL

  • Occurrence of a cardiac arrest before graft harvesting

  • Proven biopsy macrosteathosis > 30%

  • Non-opposition from the patient

Non Inclusion Criteria:

  • Fulminant hepatitis

  • Retransplantation

  • Combined organ transplantation (kidney, pancreas, heart, lung)

  • Non heart beating donor

  • Complete portal vein thrombosis on preoperative imaging finding

Exclusion

Exclusion Criteria:

  • Complete portal vein thrombosis found during procedure

  • Split liver graft

  • Realisation of a bilio-enteric anastomosis

Study Design

Total Participants: 214
Treatment Group(s): 1
Primary Treatment: temporary porto-caval shunt
Phase:
Study Start date:
March 28, 2017
Estimated Completion Date:
July 31, 2025

Connect with a study center

  • CHU Bordeaux

    Bordeaux,
    France

    Active - Recruiting

  • Hospices Civils Lyon

    Lyon,
    France

    Active - Recruiting

  • CHU Nice

    Nice,
    France

    Active - Recruiting

  • CHU Rennes

    Rennes,
    France

    Active - Recruiting

  • CHU Toulouse

    Toulouse,
    France

    Active - Recruiting

  • CHU Tours

    Tours,
    France

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.